Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2023-01-18 00:00:00 ET · period of report 2023-01-13 · accession 0000899243-23-002075 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-18 | 2023-01-13+ | VRDN | Katz Barrett | Chief Medical Off | M - OptEx | $23.03 | +29.0K | 4,147 | New | +$667.9K |
| DM | 2023-01-18 | 2023-01-13+ | VRDN | Katz Barrett | Chief Medical Off | S - Sale+OE | $37.18 | -29.0K | 0 | -100% | -$1.08M |
| DM | 2023-01-18 | 2023-01-13+ | VRDN | Katz Barrett | Chief Medical Off | M - OptEx | $0.00 | -29.0K | 267.0K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-17 | M | A | 24,853 | $23.03 | 24,853 | D | — | — | |
| 2 | Common | Common Stock | 2023-01-17 | S | D | 24,853 | $37.21 | 0 | D | — | — | |
| 3 | Common | Common Stock | 2023-01-13 | M | A | 4,147 | $23.03 | 4,147 | D | — | — | |
| 4 | Common | Common Stock | 2023-01-13 | S | D | 4,147 | $37.01 | 0 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-01-13 | M | D | 4,147 | $0.00 | 291,853 | D | $23.03 · — to 2031-01-17 | 4,147 Common Stock | (F3) The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-01-17 | M | D | 24,853 | $0.00 | 267,000 | D | $23.03 · — to 2031-01-17 | 24,853 Common Stock | (F3) The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |